Principal Financial Group Inc. Sells 100,767 Shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Principal Financial Group Inc. cut its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 5.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,645,051 shares of the specialty pharmaceutical company’s stock after selling 100,767 shares during the quarter. Principal Financial Group Inc. owned about 0.05% of Collegium Pharmaceutical worth $47,132,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. CWM LLC raised its holdings in Collegium Pharmaceutical by 97.5% in the third quarter. CWM LLC now owns 1,491 shares of the specialty pharmaceutical company’s stock worth $58,000 after purchasing an additional 736 shares during the period. TD Private Client Wealth LLC increased its stake in Collegium Pharmaceutical by 39.5% in the 3rd quarter. TD Private Client Wealth LLC now owns 1,707 shares of the specialty pharmaceutical company’s stock valued at $66,000 after buying an additional 483 shares during the last quarter. KBC Group NV increased its stake in Collegium Pharmaceutical by 72.5% in the 4th quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares during the last quarter. Nisa Investment Advisors LLC increased its stake in Collegium Pharmaceutical by 14.5% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 316 shares during the last quarter. Finally, Virtus Fund Advisers LLC bought a new position in shares of Collegium Pharmaceutical in the 3rd quarter valued at about $72,000.

Insider Buying and Selling

In related news, EVP Shirley R. Kuhlmann sold 27,500 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $33.04, for a total transaction of $908,600.00. Following the completion of the transaction, the executive vice president now directly owns 119,184 shares in the company, valued at $3,937,839.36. This represents a 18.75 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. 3.98% of the stock is owned by corporate insiders.

Collegium Pharmaceutical Price Performance

COLL stock opened at $29.75 on Friday. The company has a 50 day simple moving average of $31.00 and a 200 day simple moving average of $33.72. The stock has a market cap of $959.44 million, a price-to-earnings ratio of 12.82 and a beta of 0.82. Collegium Pharmaceutical, Inc. has a 1 year low of $28.39 and a 1 year high of $42.29. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88.

Analysts Set New Price Targets

A number of research analysts have recently commented on the stock. Needham & Company LLC raised shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price objective for the company in a research report on Friday, January 10th. Piper Sandler dropped their price objective on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research note on Tuesday, February 4th. Finally, HC Wainwright reiterated a “buy” rating and issued a $50.00 price objective on shares of Collegium Pharmaceutical in a research note on Friday, January 10th. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.